Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug

Executive Summary

FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)

You may also be interested in...



Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing

Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich

Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing

Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich

DTC Guidance Is High Priority In First Amendment Review, FDA Says

Direct-to-consumer ads are likely to be addressed by FDA early in the upcoming series of First Amendment guidances, Associate Deputy Chief Counsel Seth Ray said during the Food & Drug Law Institute Annual Education Conference in Washington, D.C. April 2

Related Content

UsernamePublicRestriction

Register

PS041930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel